Biomedical Occupation or Discipline
Deerfield raises $600M healthcare fund to invest in therapeutics, AI
Deerfield, Artificial Intelligence, Investments, Drug Development, Health care facility
FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill
United States Food and Drug Administration, Califf, Unspecified Abortion, Contraceptives, Oral, Accelerated, Artificial Intelligence, RIFs, Infrequent, Agencies
Octagon Therapeutics Ceases Operations Due to R&D Challenges and Unresolved Biology Questions
Autoimmune disease biotech, B cell immunomodulator program, OCT50 program, Novo Nordisk alliance, Winding down operations, Unresolved biology challenges
Regeneron turns to CDMO Fujifilm to boost US manufacturing capacity
Regeneron, Manufacture, Fujifilm, CDMO, Biological Factors, Capacity, United States, Boost
Chinese CRO GemPharmatech expands in San Diego as industry weighs FDA’s animal testing shift
United States Food and Drug Administration, GemPharmatech, Contract Research Organization, San Diego, Animal Testing, mouse models, expansion, Industry
FDA clears its first prescription migraine app, from Click Therapeutics
United States Food and Drug Administration, CT-132, Migraine Disorders, Click Therapeutics, click, first
Sanofi pens $1.8B research deal for 2 bispecific antibodies aimed at autoimmune, immunology
Antibodies, Bispecific, Autoimmune, Inflammatory Bowel Diseases, sanofi, Earendil Labs, Immunology, Collaboration, development aspects
Former FDA Officials Sound Alarm: Visible Changes May Be Tip of the Iceberg
United States Food and Drug Administration, public health medicine (field), Changing, Vaccines, Leadership, Policy, drug safety, Previous, KAT5 wt Allele, Icebergs, Disease Outbreaks, Alarm device, Visible
Novartis Halts Phase 2 Osteoarthritis Study of ADAMTS-5 Inhibitor Due to Lack of Pain Relief
Novartis, phase 2 trial, osteoarthritis, knee pain, ADAMTS-5 inhibitor, QUC398, M6495, clinical trial termination, pain relief, cartilage degradation, drug development
Sanofis $1.4B Kymab Bet Falters as Asthma Drug Stumbles in Phase II
Asthma, Amlitelimab, Kymab, sanofi, Immunology